Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction

被引：2

作者：

Buller, Dylan M. ^{[1
]}

Antony, Maria ^{[2
]}

Ristau, Benjamin T. ^{[1
,3
]}

机构：

[1] UConn Hlth, Div Urol, Farmington, CT USA

[2] Univ Connecticut, Sch Med, Farmington, CT USA

[3] UConn Hlth, Div Urol, 263 Farmington Ave, Farmington, CT 06030 USA

来源：

ONCOTARGETS AND THERAPY | 2023年 / 16卷

关键词：

renal cell carcinoma; adjuvant therapy; targeted therapy; immunotherapy; radiation; PRIMARY KIDNEY CANCER; EARLY BREAST-CANCER; PHASE-III TRIAL; STEREOTACTIC ABLATIVE RADIOTHERAPY; POSTOPERATIVE PROGNOSTIC NOMOGRAM; RADIOSURGERY ONCOLOGY CONSORTIUM; BODY RADIOTHERAPY; OPEN-LABEL; INTERFERON-ALPHA; RANDOMIZED-TRIAL;

D O I：

10.2147/OTT.S393296

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Locally and regionally advanced renal cell carcinoma (RCC) can recur at high rates even after visually complete resection of primary disease. Both targeted therapies and immunotherapies represent potential agents that might help reduce recurrence of RCC in these patients. This paper reviews the current body of evidence defining their potential impact and examines the large Phase III randomized clinical trials that have been performed to assess the safety and efficacy of these systemic therapies in the adjuvant setting. Given that the findings from these trials have been predominantly negative, this paper also explores the role of other potential adjuvant agents, including single and combination agent targeted therapies and immunotherapies, whose use is currently limited to metastatic RCC. Finally, the use of radiation therapy and the use of advanced imaging modalities in RCC are also considered.

引用

页码：49 / 64

页数：16

共 152 条

[91] Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

McCann, Lauren ;

Deen, Keith ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (18) :1769-1770

[92] Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Cella, David ;

Reeves, James ;

Hawkins, Robert ;

Guo, Jun ;

Nathan, Paul ;

Staehler, Michael ;

de Souza, Paul ;

Merchan, Jaime R. ;

Boleti, Ekaterini ;

Fife, Kate ;

Jin, Jie ;

Jones, Robert ;

Uemura, Hirotsugu ;

De Giorgi, Ugo ;

Harmenberg, Ulrika ;

Wang, Jinwan ;

Sternberg, Cora N. ;

Deen, Keith ;

McCann, Lauren ;

Hackshaw, Michelle D. ;

Crescenzo, Rocco ;

Pandite, Lini N. ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :722-731

[93] Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors [J].

Motzer, Robert J. ;

Escudier, Bernard ;

Oudard, Stephane ;

Hutson, Thomas E. ;

Porta, Camillo ;

Bracarda, Sergio ;

Grunwald, Viktor ;

Thompson, John A. ;

Figlin, Robert A. ;

Hollaender, Norbert ;

Kay, Andrea ;

Ravaud, Alain .

CANCER, 2010, 116 (18) :4256-4265

[94] Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Tomczak, Piotr ;

Michaelson, M. Dror ;

Bukowski, Ronald M. ;

Oudard, Stephane ;

Negrier, Sylvie ;

Szczylik, Cezary ;

Pili, Roberto ;

Bjarnason, Georg A. ;

Garcia-del-Muro, Xavier ;

Sosman, Jeffrey A. ;

Solska, Ewa ;

Wilding, George ;

Thompson, John A. ;

Kim, Sindy T. ;

Chen, Isan ;

Huang, Xin ;

Figlin, Robert A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) :3584-3590

[95] Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma [J].

Muselaers, Constantijn H. J. ;

Stillebroer, Alexander B. ;

Desar, Ingrid M. E. ;

Boers-Sonderen, Marye J. ;

van Herpen, Carla M. L. ;

de Weijert, Mirjam C. A. ;

Langenhuijsen, Johan F. ;

Oosterwijk, Egbert ;

Leenders, William P. J. ;

Boerman, Otto C. ;

Mulders, Peter F. A. ;

Oyen, Wim J. G. .

JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (02) :242-247

[96] Biomarkers of renal cell carcinoma [J].

Ngo, Tin C. ;

Wood, Christopher G. ;

Karam, Jose A. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (03) :243-251

[97] Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy [J].

Nishikawa, Masatomo ;

Miyake, Hideaki ;

Harada, Ken-ichi ;

Fujisawa, Masato .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) :49.e15-49.e21

[98] MONOCLONAL-ANTIBODY G-250 RECOGNIZES A DETERMINANT PRESENT IN RENAL-CELL CARCINOMA AND ABSENT FROM NORMAL KIDNEY [J].

OOSTERWIJK, E ;

RUITER, DJ ;

HOEDEMAEKER, PJ ;

PAUWELS, EKJ ;

JONAS, U ;

ZWARTENDIJK, J ;

WARNAAR, SO .

INTERNATIONAL JOURNAL OF CANCER, 1986, 38 (04) :489-494

[99] 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment [J].

Oosting, Sjoukje F. ;

Brouwers, Adrienne H. ;

van Es, Suzanne C. ;

Nagengast, Wouter B. ;

Munnink, Thijs H. Oude ;

Lub-de Hooge, Marjolijn N. ;

Hollema, Harry ;

de Jong, Johan R. ;

de Jong, Igle J. ;

de Haas, Sanne ;

Scherer, Stefan J. ;

Sluiter, Wim J. ;

Dierckx, Rudi A. ;

Bongaerts, Alfons H. H. ;

Gietema, Jourik A. ;

de Vries, Elisabeth G. E. .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (01) :63-69

[100] RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse [J].

Oza, Bhavna ;

Frangou, Eleni ;

Smith, Ben ;

Bryant, Hanna ;

Kaplan, Rick ;

Choodari-Oskooei, Babak ;

Powles, Tom ;

Stewart, Grant D. ;

Albiges, Laurence ;

Bex, Axel ;

Choueiri, Toni K. ;

Davis, Ian D. ;

Eisen, Tim ;

Fielding, Alison ;

Harrison, David ;

McWhirter, Anita ;

Mulhere, Salena ;

Nathan, Paul ;

Rini, Brian ;

Ritchie, Alastair ;

Scovell, Sarah ;

Shakeshaft, Clare ;

Stockler, Martin R. ;

Thorogood, Nat ;

Parmar, Mahesh K. B. ;

Larkin, James ;

Meade, Angela .

CONTEMPORARY CLINICAL TRIALS, 2021, 108

← 5 6 7 8 9 10 11 12 13 14 →